Relay Therapeutics Inc (RLAY)
NASDAQ:RLAY
Want to see RLAY full AI Analyst Report?
Total Valuation
Relay Therapeutics has a market cap or net worth of $2.59B. The enterprise value is $2.42B.
Market Cap$2.59B
Enterprise Value$2.42B
Share Statistics
Relay Therapeutics has 191,586,170 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding191,586,170
Owned by Insiders2.16%
Owned by Institutions59.31%
Financial Efficiency
Relay Therapeutics’s return on equity (ROE) is -0.49 and return on invested capital (ROIC) is -50.50%.
Return on Equity (ROE)-0.49
Return on Assets (ROA)-0.44
Return on Invested Capital (ROIC)-50.50%
Return on Capital Employed (ROCE)-0.51
Revenue Per Employee59.29K
Profits Per Employee-1.07M
Employee Count259
Asset Turnover0.02
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Relay Therapeutics is ―. Relay Therapeutics’s PEG ratio is 0.17.
PE Ratio―
PS Ratio94.54
PB Ratio2.56
Price to Fair Value2.56
Price to FCF-6.15
Price to Operating Cash Flow-11.41
PEG Ratio0.17
Income Statement
In the last 12 months, Relay Therapeutics had revenue of 15.36M and earned -276.48M in profits. Earnings per share was -1.61.
Revenue15.36M
Gross Profit11.80M
Operating Income-302.74M
Pretax Income-276.48M
Net Income-276.48M
EBITDA-272.92M
Earnings Per Share (EPS)-1.61
Cash Flow
In the last 12 months, operating cash flow was -213.36M and capital expenditures -26.00K, giving a free cash flow of -213.38M billion.
Operating Cash Flow-213.36M
Free Cash Flow-213.38M
Free Cash Flow per Share-1.11
Dividends & Yields
Relay Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.16
52-Week Price Change374.74%
50-Day Moving Average12.79
200-Day Moving Average8.32
Relative Strength Index (RSI)54.36
Average Volume (3m)3.98M
Important Dates
Relay Therapeutics upcoming earnings date is Aug 6, 2026, Before Open (Confirmed).
Last Earnings DateMay 5, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
Relay Therapeutics as a current ratio of 22.61, with Debt / Equity ratio of 4.92%
Current Ratio22.61
Quick Ratio22.61
Debt to Market Cap<0.01
Net Debt to EBITDA0.19
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Relay Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Relay Therapeutics EV to EBITDA ratio is -5.13, with an EV/FCF ratio of -5.94.
EV to Sales91.18
EV to EBITDA-5.13
EV to Free Cash Flow-5.94
EV to Operating Cash Flow-5.95
Balance Sheet
Relay Therapeutics has $642.07M in cash and marketable securities with $31.57M in debt, giving a net cash position of $610.50M billion.
Cash & Marketable Securities$642.07M
Total Debt$31.57M
Net Cash$610.50M
Net Cash Per Share$3.19
Tangible Book Value Per Share$3.30
Margins
Gross margin is 89.67%, with operating margin of -1971.59%, and net profit margin of -1800.58%.
Gross Margin89.67%
Operating Margin-1971.59%
Pretax Margin-1800.58%
Net Profit Margin-1800.58%
EBITDA Margin-1777.41%
EBIT Margin-1800.58%
Analyst Forecast
The average price target for Relay Therapeutics is $23.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$23.00
Price Target Upside37.23% Upside
Analyst ConsensusStrong Buy
Analyst Count11
Revenue Growth Forecast39.04%
EPS Growth Forecast29.88%